Advanced search
Publication Cover
HIV Research & Clinical Practice Volume 22, 2021 - Issue 6
Submit an article Journal homepage
867
Views
1
CrossRef citations to date
0
Altmetric
Brief Report

Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA study

Annegret Pelchen-Matthews1 Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0994-5655View further author information
ORCID Icon,
Jakob Friis Larsen2 CHIP Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkView further author information
,
Leah Shepherd1 Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UKView further author information
,
Josip Begovac3 University Hospital of Infectious Diseases, Zagreb, CroatiaORCID Iconhttps://orcid.org/0000-0003-2641-4327View further author information
ORCID Icon,
Karen Pedersen4 Hvidovre Universitets Hospital, Hvidovre, DenmarkView further author information
,
Stéphane De Wit5 CHU Saint-Pierre, Brussels, BelgiumView further author information
,
Andrzej Horban6 Wojewodzki Szpital Zakazny, Warsaw, PolandORCID Iconhttps://orcid.org/0000-0003-3274-4162View further author information
ORCID Icon,
Elzbieta Jablonowska7 Wojewodzki Szpital Specjalistyczny, Olsztyn, PolandView further author information
,
Margaret Johnson8 Royal Free & University College Medical School, London, UKView further author information
,
Irina Khromova9 Centre for HIV/AIDS and Infectious Diseases, Kaliningrad, RussiaView further author information
,
Marcelo H. Losso10 Hospital J.M. Ramos Mejia, Buenos Aires, ArgentinaView further author information
,
Lars N. Nielsen11 Nordsjaellands Hospital, Hillerod, DenmarkView further author information
,
Anna Lisa Ridolfo12 Ospedale L. Sacco, Milan, ItalyView further author information
,
Brigitte Schmied13 SMZ, Vienna, AustriaView further author information
,
Christoph Stephan14 Medical Dept. 2, Infectious Diseases Unit, Goethe-University Hospital, Frankfurt, GermanyView further author information
,
Israel Yust15 Ichilov Hospital, Tel Aviv, IsraelView further author information
,
Lloyd Curtis16 GlaxoSmithKline, London, UKView further author information
,
Vani Vannappagari17 ViiV Healthcare, Research Triangle, NC, USAView further author information
,
Leigh Ragone17 ViiV Healthcare, Research Triangle, NC, USAView further author information
,
Ashley Roen1 Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UKView further author information
,
Dorthe Raben2 CHIP Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkView further author information
,
Ole Kirk2 CHIP Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkView further author information
,
Lars Peters2 CHIP Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkView further author information
,
Amanda Mocroft1 Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK;2 CHIP Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkView further author information
& for the EuroSIDA Study Group show all
Pages 160-168 | Received 19 Apr 2021, Accepted 02 Nov 2021, Published online: 15 Nov 2021

References

  • Trivedi J, Mahajan D, Jaffe RJ, Acharya A, Mitra D, Byrareddy SN. Recent advances in the development of integrase inhibitors for HIV treatment. Curr HIV/AIDS Rep. 2020;17(1):63–75.
  • Brooks KM, Sherman EM, Egelund EF, et al. Integrase inhibitors: after 10 years of experience, is the best yet to come? Pharmacotherapy 2019;39(5):576–598.
  • World Health Organization Geneva Switzerland. Update of Recommendations on First- and Second-Line Antiretroviral Regimens. https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf?ua=1. Updated July 2019. Accessed July 2020.
  • EACS (European AIDS Clinical Society). EACS Guidelines Version 10.0. https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html. Updated November 2019. Accessed January 2021.
  • Vitoria M, Hill A, Ford N, et al. The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues? AIDS. 2018;32(12):1551–1561.
  • Inzaule SC, Hamers RL, Doherty M, Shafer RW, Bertagnolio S, Rinke de Wit TF. Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens. Lancet Infect Dis. 2019;19(7):e246–e252.
  • Phillips AN, Venter F, Havlir D, et al. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. Lancet HIV. 2019;6(2):e116–e127.
  • Castagna A, Maggiolo F, Penco G, for the VIKING-3 Study Group, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210(3):354–362.
  • Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735–743.
  • Curtis L, Nichols G, Stainsby C, et al. Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients. HIV Clin Trials. 2014;15(5):199–208.
  • Hughes CA, Foisy MM, Dewhurst N, et al. Abacavir hypersensitivity reaction: an update. Ann Pharmacother. 2008;42(3):387–396.
  • Laut K, Kirk O, Rockstroh J, et al. The EuroSIDA study: 25 years of scientific achievements. HIV Med. 2020;21(2):71–83.
  • European Association for the Study of the Liver. EASL Clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019;70(6):1222–1261.
  • U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf. Updated July 2017. Accessed July 2020.
  • Elzi L, Erb S, Furrer H, et al. Adverse events of raltegravir and dolutegravir. AIDS. 2017;31(13):1853–1858.
  • Hongo H, Nagao T, Nakamura K, et al. Safety and effectiveness analysis of dolutegravir in patients with HIV-1: interim report of post-marketing surveillance in Japan. Adv Ther. 2021; 38(8):4480–4504.
  • Llibre JM, Montoliu A, Miro JM, et al. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort. HIV Med. 2019;20(3):237–247.
  • Penafiel J, de Lazzari E, Padilla M, et al. Tolerability of integrase inhibitors in a real-life setting. J Antimicrob Chemother. 2017;72(6):1752–1759.
  • Scevola S, Tiraboschi JM, Podzamczer D. Nothing is perfect: the safety issues of integrase inhibitor regimens. Expert Opin Drug Saf. 2020;19(6):683–694.
  • Martin C, Payen MC, De Wit S. Dolutegravir as a trigger for DRESS syndrome? Int J STD AIDS. 2018;29(10):1036–1038.
  • Nhean S, Yoong D, Wong DK, Gough K, Tseng AL. Probable hepatotoxicity with dolutegravir: report of two cases and review of the literature. AIDS. 2019;33(7):1261–1263.
  • Cento V, Perno CF. Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: latest evidence from the literature on their efficacy and safety. J Glob Antimicrob Resist. 2020;20:228–237.
  • Lepik KJ, Harrigan PR, Yip B, et al. Emergent drug resistance with integrase strand transfer inhibitor-based regimens. AIDS. 2017;31(10):1425–1434.
  • Brehm TT, Franz M, Hufner A, et al. Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naive and -experienced patients. Medicine. 2019;98(32):e16721.
  • Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18(1):56–63.
  • Greenberg L, Ryom L, Wandeler G, et al. Uptake and discontinuation of integrase inhibitors (INSTIs) in a large cohort setting. J Acquir Immune Defic Syndr. 2020;83(3):240–250.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.